News & Media

San Diego, Calif., June 20, 2019 - Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), has joined the UC San Diego Center for Microbiome Innovation (CMI) Industry Member board. Consistent with Otsuka’s nearly 100-year tradition, OPDC is dedicated to the research and clinical development of products that could have a major impact on human health with a focus on neuroscience,

Approach combines Otsuka’s expertise in developing and commercializing treatments for mental health with Click’s record of discovering and validating digital technologies as prescription medical treatments SAN FRANCISCO, C.A. and NEW YORK, N.Y. -- January, 3, 2019 – Otsuka America, Inc., and Click Therapeutics, Inc., announce today that the companies have signed a collaboration

Panel of Noted Mental Health Experts, Policy Leaders and Advocates Review Progress, Identify Opportunities to Shape Future Policy to Advance Care Over the Next Decade and Beyond WASHINGTON, DC – November 28, 2018 – Otsuka America Pharmaceutical, Inc. (Otsuka), a global leader in developing solutions to meet unmet mental health needs, today hosted the Advancing Mental Health Policy Forum

Engagement with legislators and advocates about innovation in health and technology to address critical public health issues affecting underserved communities WASHINGTON, D.C. – November 16, 2018 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a global leader in the development of digital and traditional treatments for mental illness, together with honorary